Scancell (LON:SCLP) Hits New 52-Week Low – Here’s What Happened

Scancell Holdings plc (LON:SCLP)’s stock price hit a new 52-week low during mid-day trading on Tuesday. The company traded as low as GBX 79.80 and last traded at GBX 81, with a volume of 751,889 shares traded. The stock had previously closed at GBX 81.

Scancell Price Performance

The stock has a market capitalization of £1.09 billion, a PE ratio of -145.64 and a beta of 0.69. The company has a debt-to-equity ratio of -88.01, a current ratio of 0.28 and a quick ratio of 13.01. The stock’s 50 day moving average is GBX 93.66 and its two-hundred day moving average is GBX 131.76.

Scancell (LON:SCLP) last posted its earnings results on Friday, October 9th. The company reported GBX (17.30) EPS for the quarter. Scancell had a positive return on equity of 128.87% and a negative net margin of 116.98%. As a group, sell-side analysts forecast that Scancell Holdings plc will post -2.54 earnings per share for the current fiscal year.

Scancell Company Profile

Scancell (LSE:SCLP) is a clinical stage company leveraging two proprietary platforms, Immunobody® and Moditope®, to develop targeted off-the-shelf, patient-accessible active immunotherapies for a cancer-free future. The lead product iSCIB1+ is an Immunobody® DNA active immunotherapy that has demonstrated monotherapy activity in adjuvant melanoma. When combined with checkpoint therapies it showed additional clinical benefit over the checkpoints (CPI) alone in the ongoing Phase 2 SCOPE trial in advanced melanoma.